#Taiwan #Taipei #ADC Development #Mycenax Biotech #RIN Institute

Mycenax Biotech and RIN Institute: A Strategic Collaboration in ADC Development

In an important move within the biotechnology sector, Mycenax Biotech Inc. has recently announced a significant licensing agreement with the Japanese firm, RIN Institute Inc. This partnership permits Mycenax to utilize RIN's proprietary Val-Leu-Lys (VLK) linker technology globally for Contract Development and Manufacturing Organization (CDMO) services. Notably, RIN's VLK linker has demonstrated superior anti-tumor efficacy and high serum stability, which is pivotal for the development of advanced antibody-drug conjugates (ADCs).

The VLK linker from RIN enables targeted cytotoxicity by employing two mechanisms: the enhanced effects within the tumor microenvironment and improved ADC internalization. This innovative approach is anticipated to bolster Mycenax's ability to deliver differentiated ADC solutions to its global pharmaceutical partners, thereby revolutionizing cancer therapeutics.

Pei-Jiun Chen, the CEO and President of Mycenax, expressed enthusiasm regarding the agreement, deeming it a crucial milestone in the company's mission to provide innovative and competitive ADC solutions. This collaboration not only enhances Mycenax's technical capabilities but also solidifies its commitment to advancing next-generation ADC therapeutics.

This partnership builds upon an earlier understanding established on April 7, 2025, which laid the groundwork for enhanced collaboration between Mycenax and RIN in the promotion of ADC innovations.

Insight into RIN Institute

Founded in January 2016, RIN Institute was established to develop antibody medications for cancer, based on the groundbreaking research of Dr. Yasuhiro Matsumura, a former head of the therapeutic development department at the National Cancer Center (NCC). RIN operates as a spin-off biotech entity from NCC and focuses on fostering collaborative research in developing ADCs. The company's laboratory serves as a pivotal research base, enhancing collaborative projects with NCC, with ongoing advancements having been made in ADCs and novel thrombolytic fusion proteins.

RIN commenced the Phase 1 study of its leading product—a humanized anti-TMEM180 antibody—at the NCC in January 2023. With the support of NCC, RIN aims to propel the development of new and innovative antibodies for both therapeutic and diagnostic applications in oncology.

About Mycenax Biotech Inc.

Mycenax Biotech Inc., headquartered in Taiwan, stands as a prominent CDMO provider for biological products, offering integrated solutions ranging from cell line development to drug manufacturing. With two GMP-compliant facilities that have received approvals from multiple regulatory bodies, including EMA, PMDA, and Health Canada, Mycenax provides end-to-end manufacturing services.

To meet the growing global demand, Mycenax is advancing its ADC-CDMO expertise through partnerships with firms such as KriSan Biotech and Spera Pharma, focusing on specific conjugation and multi-arm linker technology. Additionally, the company collaborates with Alfresa Holdings, Kidswell Bio, and Chiome Bioscience under the Japanese MHLW support program for biosimilar production. With a commitment to enhancing its capabilities, Mycenax aims to further solidify its position in the biotechnology landscape.

For more information, please visit Mycenax's official website.